Tekla Capital Management LLC Chinook Therapeutics, Inc. Call Options Transaction History
Tekla Capital Management LLC
- $2.53 Billion
- Q2 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KDNY
# of Institutions
5Shares Held
234KCall Options Held
0Put Options Held
0About CHINOOK THERAPEUTICS, INC.
- Ticker KDNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,896,300
- Description
- Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...